A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.3 billion in 2014. We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules ...
A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.3 billion in 2014. We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry. The complexities of severe diseases are beyond the expertise and resources of a single organisation.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.